SG11201509924WA - Composition for maintaining function of platelets - Google Patents

Composition for maintaining function of platelets

Info

Publication number
SG11201509924WA
SG11201509924WA SG11201509924WA SG11201509924WA SG11201509924WA SG 11201509924W A SG11201509924W A SG 11201509924WA SG 11201509924W A SG11201509924W A SG 11201509924WA SG 11201509924W A SG11201509924W A SG 11201509924WA SG 11201509924W A SG11201509924W A SG 11201509924WA
Authority
SG
Singapore
Prior art keywords
platelets
composition
maintaining function
maintaining
function
Prior art date
Application number
SG11201509924WA
Inventor
Shinji Hirata
Takahiko Murata
Koji Eto
Original Assignee
Kaken Pharma Co Ltd
Univ Kyoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharma Co Ltd, Univ Kyoto filed Critical Kaken Pharma Co Ltd
Publication of SG11201509924WA publication Critical patent/SG11201509924WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C12N2501/734—Proteases (EC 3.4.)
SG11201509924WA 2013-06-07 2014-06-06 Composition for maintaining function of platelets SG11201509924WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013120696 2013-06-07
PCT/JP2014/065061 WO2014196624A1 (en) 2013-06-07 2014-06-06 Composition for maintaining platelet function

Publications (1)

Publication Number Publication Date
SG11201509924WA true SG11201509924WA (en) 2016-01-28

Family

ID=52008253

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201509924WA SG11201509924WA (en) 2013-06-07 2014-06-06 Composition for maintaining function of platelets

Country Status (9)

Country Link
US (1) US20160168540A1 (en)
EP (1) EP3006029A4 (en)
JP (1) JPWO2014196624A1 (en)
KR (1) KR20160018517A (en)
CN (1) CN105392482B (en)
AU (1) AU2014275836A1 (en)
CA (1) CA2914326A1 (en)
SG (1) SG11201509924WA (en)
WO (1) WO2014196624A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201210857D0 (en) 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
CN105101979B (en) 2012-12-21 2021-10-08 安斯泰来再生医药协会 Method for preparing platelets from pluripotent stem cells and composition thereof
AU2017332937B2 (en) * 2016-09-23 2021-01-14 Kaken Pharmaceutical Co., Ltd. Method for producing (R)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione and intermediate for producing same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058064B2 (en) 2006-10-04 2011-11-15 The University Of Tokyo Sac-like structure enclosing hematopoietic progenitor cells produced from ES cells and method for preparing blood cells
JPWO2009119105A1 (en) 2008-03-28 2011-07-21 国立大学法人 東京大学 GPIbα + GPV + GPVI + platelet in vitro preparation method
WO2009122747A1 (en) 2008-04-01 2009-10-08 国立大学法人東京大学 Method for preparation of platelet from ips cell
EP2617812B1 (en) * 2010-09-17 2019-03-20 The University of Tokyo Composition for maintaining platelet function
WO2013085016A1 (en) * 2011-12-09 2013-06-13 科研製薬株式会社 Pyridone derivative and medicine containing same
TWI636782B (en) * 2013-06-07 2018-10-01 科研製藥股份有限公司 (+)-5-(3,4-difluorphenyl)-5-{(3-methyl-2-oxopyridine-1(2h)-yl)methyl}imidazolidine-2,4-dione and pharmaceuticals containing the same

Also Published As

Publication number Publication date
KR20160018517A (en) 2016-02-17
CN105392482A (en) 2016-03-09
WO2014196624A1 (en) 2014-12-11
US20160168540A1 (en) 2016-06-16
EP3006029A4 (en) 2017-01-04
CN105392482B (en) 2017-08-08
EP3006029A1 (en) 2016-04-13
JPWO2014196624A1 (en) 2017-02-23
CA2914326A1 (en) 2014-12-11
AU2014275836A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
GB201319525D0 (en) Composition
EP2889350A4 (en) Tacky-adhesive composition
HRP20181710T1 (en) Use of benzimidazole-proline derivatives
EP3006525A4 (en) Asphalt-urethane composition
GB201319540D0 (en) Composition
GB201318489D0 (en) Composition
GB201317388D0 (en) Composition
EP3066178A4 (en) Lumbricant composition
GB201319538D0 (en) Composition
IL240763A0 (en) Halogenopyrazoles as inhibitors of therombin
GB201306984D0 (en) Composition
GB201320303D0 (en) Composition
GB201317196D0 (en) Composition
GB201307622D0 (en) Composition
HRP20182110T1 (en) Composition of tiacumicin compounds
SG11201509924WA (en) Composition for maintaining function of platelets
GB201308502D0 (en) Composition
GB201301774D0 (en) Composition
GB201318394D0 (en) Composition
HK1204865A1 (en) Composition for elimination of troublesome varmints
KR102216470B9 (en) Composition of Natural Substance
GB201305622D0 (en) Composition
HK1198422A1 (en) Novel uses of colossolactones
GB201315461D0 (en) Composition of phosphonates
PL3071575T3 (en) Preparation of normorphinans